Effect of transporter inhibition on the distribution of cefadroxil in rat brain

Fluids and Barriers of the CNS

Margareta Hammarlund-Udenaes³  David E Smith⁴  Richard F Keep¹  Maryam Payan²  Irena Loryan³  Xiaomei Chen³ 

[1] Department of Neurosurgery, University of Michigan Health System, Ann Arbor, MI 48109, USA;Biopharmaceutics and Pharmacokinetic Division, Department of Pharmaceutics, Faculty of Pharmacy, Tehran University of Medical Sciences, Tehran, Iran;Department of Pharmaceutical Biosciences, Translational PKPD Research Group, Uppsala University, Box 591, SE-75124 Uppsala, Sweden;Department of Pharmaceutical Sciences, College of Pharmacy, University of Michigan, Ann Arbor, Mi 48109, USA

关键词: Probenecid;    Peptide transporter 2;    Organic anion transporting polypeptides;    Organic anion transporters;    Multidrug resistance-associated proteins;    Cefadroxil;    Brain slice;    Intracerebral microdialysis;    Blood-cerebrospinal fluid barrier;    Blood–brain barrier;   

Others  :  1098235
DOI  :  10.1186/2045-8118-11-25

 received in 2014-08-18, accepted in 2014-10-18,  发布年份 2014

【 摘 要 】

Background

Cefadroxil, a cephalosporin antibiotic, is a substrate for several membrane transporters including peptide transporter 2 (PEPT2), organic anion transporters (OATs), multidrug resistance-associated proteins (MRPs), and organic anion transporting polypeptides (OATPs). These transporters are expressed at the blood–brain barrier (BBB), blood-cerebrospinal fluid barrier (BCSFB), and/or brain cells. The effect of these transporters on cefadroxil distribution in brain is unknown, especially in the extracellular and intracellular fluids within brain.

Methods

Intracerebral microdialysis was used to measure unbound concentrations of cefadroxil in rat blood, striatum extracellular fluid (ECF) and lateral ventricle cerebrospinal fluid (CSF). The distribution of cefadroxil in brain was compared in the absence and presence of probenecid, an inhibitor of OATs, MRPs and OATPs, where both drugs were administered intravenously. The effect of PEPT2 inhibition by intracerebroventricular (icv) infusion of Ala-Ala, a substrate of PEPT2, on cefadroxil levels in brain was also evaluated. In addition, using an in vitro brain slice method, the distribution of cefadroxil in brain intracellular fluid (ICF) was studied in the absence and presence of transport inhibitors (probenecid for OATs, MRPs and OATPs; Ala-Ala and glycylsarcosine for PEPT2).

Results

The ratio of unbound cefadroxil AUC in brain ECF to blood (K_p,uu,ECF) was ~2.5-fold greater during probenecid treatment. In contrast, the ratio of cefadroxil AUC in CSF to blood (K_p,uu,CSF) did not change significantly during probenecid infusion. Icv infusion of Ala-Ala did not change cefadroxil levels in brain ECF, CSF or blood. In the brain slice study, Ala-Ala and glycylsarcosine decreased the unbound volume of distribution of cefadroxil in brain (V_u,brain), indicating a reduction in cefadroxil accumulation in brain cells. In contrast, probenecid increased cefadroxil accumulation in brain cells, as indicated by a greater value for V_u,brain.

Conclusions

Transporters (OATs, MRPs, and perhaps OATPs) that can be inhibited by probenecid play an important role in mediating the brain-to-blood efflux of cefadroxil at the BBB. The uptake of cefadroxil in brain cells involves both the influx transporter PEPT2 and efflux transporters (probenecid-inhibitable). These findings demonstrate that drug-drug interactions via relevant transporters may affect the distribution of cephalosporins in both brain ECF and ICF.

【 授权许可】

   
2014 Chen et al.; licensee BioMed Central Ltd.

【 图 表 】

Figure 1.

Figure 2.

Figure 3.

Figure 4.

Figure 5.

Figure 6.

【 参考文献 】

• [1]Brunton LL, Chabner BA, Knollmann BC: Goodman & Gilman’s The Pharmacological Basis of Therapeutics. 12th edition. New York: McGraw-Hill; 2011.
• [2]Brandsch M, Knutter I, Bosse-Doenecke E: Pharmaceutical and pharmacological importance of peptide transporters. J Pharm Pharmacol 2008, 60:543-585.
• [3]Burckhardt G: Drug transport by Organic Anion Transporters (OATs). Pharmacol Ther 2012, 136:106-130.
• [4]Nakakariya M, Shimada T, Irokawa M, Koibuchi H, Iwanaga T, Yabuuchi H, Maeda T, Tamai I: Predominant contribution of rat organic anion transporting polypeptide-2 (Oatp2) to hepatic uptake of beta-lactam antibiotics. Pharm Res 2008, 25:578-585.
• [5]Nakakariya M, Shimada T, Irokawa M, Maeda T, Tamai I: Identification and species similarity of OATP transporters responsible for hepatic uptake of beta-lactam antibiotics. Drug Metab Pharmacokinet 2008, 23:347-355.
• [6]Akanuma S, Uchida Y, Ohtsuki S, Kamiie J, Tachikawa M, Terasaki T, Hosoya K: Molecular-weight-dependent, anionic-substrate-preferential transport of beta-lactam antibiotics via multidrug resistance-associated protein 4. Drug Metab Pharmacokinet 2011, 26:602-611.
• [7]Kato Y, Takahara S, Kato S, Kubo Y, Sai Y, Tamai I, Yabuuchi H, Tsuji A: Involvement of multidrug resistance-associated protein 2 (Abcc2) in molecular weight-dependent biliary excretion of beta-lactam antibiotics. Drug Metab Dispos 2008, 36:1088-1096.
• [8]Giacomini KM, Huang SM, Tweedie DJ, Benet LZ, Brouwer KL, Chu X, Dahlin A, Evers R, Fischer V, Hillgren KM, Hoffmaster KA, Ishikawa T, Keppler D, Kim RB, Lee CA, Niemi M, Polli JW, Sugiyama Y, Swaan PW, Ware JA, Wright SH, Yee SW, Zamek-Gliszczynski MJ, Zhang L: Membrane transporters in drug development. Nat Rev Drug Discov 2010, 9:215-236.
• [9]Abbott NJ, Patabendige AA, Dolman DE, Yusof SR, Begley DJ: Structure and function of the blood–brain barrier. Neurobiol Dis 2010, 37:13-25.
• [10]Abbott NJ: Blood–brain barrier structure and function and the challenges for CNS drug delivery. J Inherit Metab Dis 2013, 36:437-449.
• [11]Saunders NR, Habgood MD, Dziegielewska KM: Barrier mechanisms in the brain, I. adult brain. Clin Exp Pharmacol Physiol 1999, 26:11-19.
• [12]Kusuhara H, Sugiyama Y: Efflux transport systems at the blood–brain barrier and blood CSF barrier. In Drug Transport(ers) and the Diseased Brain 1277 edition. Edited by DeBoer AG. 2005, 111-122. [International Congress Series]
• [13]Hartz AMS, Bauer B: ABC Transporters in the CNS - an inventory. Curr Pharm Biotechno 2011, 12:656-673.
• [14]Farthing CA, Sweet DH: Expression and function of organic cation and anion transporters (SLC22 family) in the CNS. Curr Pharm Design 2014, 20:1472-1486.
• [15]Loscher W, Potschka H: Role of drug efflux transporters in the brain for drug disposition and treatment of brain diseases. Prog Neurobiol 2005, 76:22-76.
• [16]Smith DE, Johanson CE, Keep RF: Peptide and peptide analog transport systems at the blood-CSF barrier. Adv Drug Deliv Rev 2004, 56:1765-1791.
• [17]Westholm DE, Rumbley JN, Salo DR, Rich TP, Anderson GW: Organic anion-transporting polypeptides at the blood–brain and blood-cerebrospinal fluid barriers. Curr Top Dev Biol 2008, 80:135-170.
• [18]Ronaldson PT, Davis TP: Targeted drug delivery to treat pain and cerebral hypoxia. Pharmacol Rev 2013, 65:291-314.
• [19]Xiang J, Chiang PP, Hu Y, Smith DE, Keep RF: Role of PEPT2 in glycylsarcosine transport in astrocyte and glioma cultures. Neurosci Lett 2006, 396:225-229.
• [20]Shen H, Ocheltree SM, Hu Y, Keep RF, Smith DE: Impact of genetic knockout of PEPT2 on cefadroxil pharmacokinetics, renal tubular reabsorption, and brain penetration in mice. Drug Metab Dispos 2007, 35:1209-1216.
• [21]Khamdang S, Takeda M, Babu E, Noshiro R, Onozato ML, Tojo A, Enomoto A, Huang XL, Narikawa S, Anzai N, Piyachaturawat P, Endou H: Interaction of human and rat organic anion transporter 2 with various cephalosporin antibiotics. Eur J Pharmacol 2003, 465:1-7.
• [22]de Waart DR, van de Wetering K, Kunne C, Duijst S, Paulusma CC, Oude Elferink RP: Oral availability of cefadroxil depends on ABCC3 and ABCC4. Drug Metab Dispos 2012, 40:515-521.
• [23]Garcia-Carbonell MC, Granero L, Torres-Molina F, Aristorena JC, Chesa-Jimenez J, Pla-Delfina JM, Peris-Ribera JE: Nonlinear pharmacokinetics of cefadroxil in the rat. Drug Metab Dispos 1993, 21:215-217.
• [24]Posada MM, Smith DE: Relevance of PepT1 in the intestinal permeability and oral absorption of Cefadroxil. Pharm Res 2013, 30:1017-1025.
• [25]Marino EL, Dominguezgil A: The pharmacokinetics of Cefadroxil associated with probenecid. Int J Clin Pharm Th 1981, 19:506-508.
• [26]Sugiyama D, Kusuhara H, Shitara Y, Abe T, Meier PJ, Sekine T, Endou H, Suzuki H, Sugiyama Y: Characterization of the efflux transport of 17beta-estradiol-D-17beta-glucuronide from the brain across the blood–brain barrier. J Pharmacol Exp Ther 2001, 298:316-322.
• [27]Luna-Tortos C, Fedrowitz M, Loscher W: Evaluation of transport of common antiepileptic drugs by human multidrug resistance-associated proteins (MRP1, 2 and 5) that are overexpressed in pharmacoresistant epilepsy. Neuropharmacology 2010, 58:1019-1032.
• [28]Ocheltree SM, Shen H, Hu Y, Xiang J, Keep RF, Smith DE: Mechanisms of cefadroxil uptake in the choroid plexus: studies in wild-type and PEPT2 knockout mice. J Pharmacol Exp Ther 2004, 308:462-467.
• [29]Jiang H, Hu Y, Keep RF, Smith DE: Enhanced antinociceptive response to intracerebroventricular kyotorphin in Pept2 null mice. J Neurochem 2009, 109:1536-1543.
• [30]Xiang J, Jiang H, Hu Y, Smith DE, Keep RF: Kyotorphin transport and metabolism in rat and mouse neonatal astrocytes. Brain Res 2010, 1347:11-18.
• [31]Xie RJ, Bouw MR, Hammarlund-Udenaes M: Modelling of the blood–brain barrier transport of morphine-3-glucuronide studied using microdialysis in the rat: involvement of probenecid-sensitive transport. Br J Pharmacol 2000, 131:1784-1792.
• [32]Bengtsson J, Bostrom E, Hammarlund-Udenaes M: The use of a deuterated calibrator for in vivo recovery estimations in microdialysis studies. J Pharm Sci 2008, 97:3433-3441.
• [33]Loryan I, Friden M, Hammarlund-Udenaes M: The brain slice method for studying drug distribution in the CNS. Fluids Barriers CNS 2013, 10:6. BioMed Central Full Text
• [34]Friden M, Ducrozet F, Middleton B, Antonsson M, Bredberg U, Hammarlund-Udenaes M: Development of a high-throughput brain slice method for studying drug distribution in the central nervous system. Drug Metab Dispos 2009, 37:1226-1233.
• [35]Huh Y, Keep RF, Smith DE: Impact of lipopolysaccharide-induced inflammation on the disposition of the aminocephalosporin cefadroxil. Antimicrob Agents Chemother 2013, 57:6171-6178.
• [36]Hammarlund-Udenaes M, Friden M, Syvanen S, Gupta A: On the rate and extent of drug delivery to the brain. Pharm Res 2008, 25:1737-1750.
• [37]Giacomini KM, Huang SM: Transporters in drug development and clinical pharmacology. Clin Pharmacol Ther 2013, 94:3-9.
• [38]Mahringer A, Ott M, Reimold I, Reichel V, Fricker G: The ABC of the blood–brain barrier - regulation of drug efflux pumps. Curr Pharm Design 2011, 17:2762-2770.
• [39]Keep RF, Smith DE: Choroid plexus transport: gene deletion studies. Fluids Barriers CNS 2011, 8:26. BioMed Central Full Text
• [40]Redzic Z: Molecular biology of the blood–brain and the blood-cerebrospinal fluid barriers: similarities and differences. Fluids Barriers CNS 2011, 8:3. BioMed Central Full Text
• [41]Miller DS: ABC transporters at the blood–brain barrier. Top Med Chem 2013. doi:10.1007/7355_2013_31
• [42]Abbott NJ, Ronnback L, Hansson E: Astrocyte-endothelial interactions at the blood–brain barrier. Nat Rev Neurosci 2006, 7:41-53.
• [43]Westerhout J, van den Berg DJ, Hartman R, Danhof M, de Lange EC: Prediction of methotrexate CNS distribution in different species - influence of disease conditions. Eur J Pharm Sci 2014, 57:11-24.
• [44]Deguchi Y, Nozawa K, Yamada S, Yokoyama Y, Kimura R: Quantitative evaluation of brain distribution and blood–brain barrier efflux transport of probenecid in rats by microdialysis: possible involvement of the monocarboxylic acid transport system. J Pharmacol Exp Ther 1997, 280:551-560.
• [45]Bourne A, Barnes K, Taylor BA, Turner AJ, Kenny AJ: Membrane peptidases in the pig choroid plexus and on other cell surfaces in contact with the cerebrospinal fluid. Biochem J 1989, 259:69-80.
• [46]Shen H, Smith DE, Keep RF, Brosius FC 3rd: Immunolocalization of the proton-coupled oligopeptide transporter PEPT2 in developing rat brain. Mol Pharm 2004, 1:248-256.
• [47]Scism JL, Powers KM, Artru AA, Lewis L, Shen DD: Probenecid-inhibitable efflux transport of valproic acid in the brain parenchymal cells of rabbits: a microdialysis study. Brain Res 2000, 884:77-86.
• [48]Hammarlund-Udenaes M: The use of microdialysis in CNS drug delivery studies - pharmacokinetic perspectives and results with analgesics and antiepileptics. Adv Drug Deliv Rev 2000, 45:283-294.
• [49]Friden M, Gupta A, Antonsson M, Bredberg U, Hammarlund-Udenaes M: In vitro methods for estimating unbound drug concentrations in the brain interstitial and intracellular fluids. Drug Metab Dispos 2007, 35:1711-1719.
• [50]Meli DN, Christen S, Leib SL, Tauber MG: Current concepts in the pathogenesis of meningitis caused by Streptococcus pneumoniae. Curr Opin Infect Dis 2002, 15:253-257.
• [51]Tunkel AR, Scheld WM: Pathogenesis and pathophysiology of bacterial-meningitis. Clin Microbiol Rev 1993, 6:118-136.
• [52]Tunkel AR, Hartman BJ, Kaplan SL, Kaufman BA, Roos KL, Scheld WM, Whitley RJ: Practice guidelines for the management of bacterial meningitis. Clin Infect Dis 2004, 39:1267-1284.
• [53]Kumar V, Abbas AK, Fausto N, Robbins SL, Cotran RS: Robbins and Cotran Pathologic Basis of Disease. Philadelphia: Elsevier Saunders; 2005.
• [54]Robbins N, Koch SE, Tranter M, Rubinstein J: The history and future of probenecid. Cardiovasc Toxicol 2012, 12:1-9.